Loading...
Docoh

Regulus Therapeutics (RGLS)

Utility
MicroRNA Compounds and Methods for Modulating MIR-10B Activity
31 Mar 22
Described herein are compositions and methods for the inhibition of miR-10b activity.
Charles R. Allerson
Filed: 12 Nov 19
Utility
Methods for Oral Delivery of Oligonucleotides
31 Mar 22
Provided herein are methods for oral administration of oligonucleotides.
Timothy Wright
Filed: 19 Jul 19
Utility
Methods for Treatment of Polycystic Kidney Disease
27 Jan 22
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
John R. ANDROSAVICH, B. Nelson CHAU, Vishal D. PATEL
Filed: 5 Oct 21
Utility
Methods for treatment of polycystic kidney disease
9 Nov 21
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
John R. Androsavich, B. Nelson Chau, Vishal D. Patel
Filed: 19 Mar 20
Utility
Galnac Conjugated Modified Oligonucleotides as MIR-122 Inhibitor Having HCV Antiviral Activity with Reduced Hyperbilirubinemia Side-Effect
10 Jun 21
Described herein are compositions and methods for the inhibition of miR-122 activity.
Charles R. Allerson, Steven S. Neben, Timothy Wright
Filed: 7 May 19
Utility
Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
1 Apr 21
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Charles R. Allerson
Filed: 25 Sep 20
Utility
Compounds and methods for enhanced cellular uptake
9 Mar 21
Described herein are conjugated modified oligonucleotides that are complementary to a target RNA.
Balkrishen Bhat
Filed: 17 Jan 19
Utility
Methods for Treatment of Polycystic Kidney Disease
16 Dec 20
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
Filed: 26 Aug 20
Utility
Methods and Compositions for Treatment of Polycystic Kidney Disease
16 Dec 20
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
Filed: 26 Aug 20
Utility
Methods for Treatment of Polycystic Kidney Disease
22 Jul 20
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
John R. ANDROSAVICH, B. Nelson CHAU, Vishal D. PATEL
Filed: 18 Mar 20
Utility
Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
27 May 20
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Charles R. Allerson
Filed: 3 Dec 17
Utility
Methods for treatment of polycystic kidney disease
27 Apr 20
Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
John R. Androsavich, B. Nelson Chau, Vishal D. Patel
Filed: 24 Aug 16
Utility
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
9 Mar 20
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs.
C. Frank Bennett, Susan M. Freier, Richard H. Griffey
Filed: 5 Sep 18
Utility
Methods for Treatment of Polycystic Kidney Disease
13 Nov 19
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
Filed: 3 Dec 17
Utility
Compounds and Methods for Enhanced Cellular Uptake
9 Oct 19
Described herein are conjugated modified oligonucleotides that are complementary to a target RNA.
Balkrishen Bhat
Filed: 16 Jan 19
  • 1
Patents are sorted by USPTO publication date, most recent first